Biodesix, Inc.
NASDAQ:BDSXMedical - Diagnostics & Research
+$2.04 today
- Market cap
- $68.38M
- Beta
- 0.59
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$3.31
Volume 0.17M
Average 0.06M
BDSX Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Biodesix, Inc.NASDAQ: BDSX
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin widens to 83.5%
Gross margin was 83.5% in Q1 FY2026, up 4.2 pp from a year earlier. On a trailing-twelve-month basis it was 82.1%, up 3.7 pp year over year. Over 3 fiscal years it widened by 18.1 pp.
Context
- Gross margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 81.1%
- Year-over-year change
- +2.9pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81.1% | +2.9pp |
| FY2024 | 2024-12-31 | 78.2% | +4.7pp |
| FY2023 | 2023-12-31 | 73.5% | +10.5pp |
| FY2022 | 2022-12-31 | 63.0% | +18.9pp |
| FY2021 | 2021-12-31 | 44.0% | — |
Gross Margin vs competitors
How BDSX compares with its peers on the latest reported figures
- BDSX's LTM Mar 2026 gross margin of 82.1% is the 2nd highest of the 3 companies compared; the peer median is 85.3%.
- Its year-over-year change of +3.7 pp is the highest of 3, against a peer median of -14.7 pp.
- Over three fiscal years its change of +18.1 pp compares with a peer median of +0.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 100.0% | +0.0 pp | +0.0 pp | |
| LTM Mar 2026 | 82.1% | +3.7 pp | +18.1 pp | |
| LTM Mar 2026 | 70.7% | -29.3 pp | — | |
OKUROnKure Therapeutics, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding BDSX) | 85.3% | -14.7 pp | +0.0 pp | |
Competitors are the stored peer set for BDSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 54.51M | 38.21M | 49.09M | 71.32M | 88.5M |
| Cost of Revenue | 30.52M | 14.15M | 13.01M | 15.57M | 16.72M |
| Gross Profit | 23.99M | 24.06M | 36.08M | 55.75M | 71.78M |
| Gross Margin | 44.0% | 63.0% | 73.5% | 78.2% | 81.1% |
| Research & Development | 12.79M | 13.1M | 9.99M | 9.56M | 12M |
| Selling, General & Admin | 50.52M | 61.46M | 67.39M | 80.45M | 87.55M |
| Operating Expenses | 64.93M | 74.65M | 77.42M | 90.25M | 99.55M |
| Depreciation & Amortization | 3.18M | 5.84M | 5.51M | 5.46M | 5.6M |
| EBITDA | (35.47M) | (51.53M) | (37.1M) | (29.22M) | (21.95M) |
| EBITDA Margin | -65.1% | -134.9% | -75.6% | -41.0% | -24.8% |
| Operating Income | (40.94M) | (50.59M) | (41.34M) | (34.5M) | (27.77M) |
| Operating Margin | -75.1% | -132.4% | -84.2% | -48.4% | -31.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 4.51M | 8.07M | 9.54M | 8.26M | 7.72M |
| Other Income / Expenses | (2.22M) | (14.86M) | (10.8M) | (8.43M) | (7.5M) |
| Income Before Tax | (43.16M) | (65.45M) | (52.15M) | (42.93M) | (35.27M) |
| Pre-Tax Margin | -79.2% | -171.3% | -106.2% | -60.2% | -39.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.16M) | (65.45M) | (52.15M) | (42.93M) | (35.27M) |
| Net Margin | -79.2% | -171.3% | -106.2% | -60.2% | -39.8% |
| EPS (Basic) | (31.60) | (31.00) | (12.80) | (6.60) | (4.67) |
| EPS (Diluted) | (31.60) | (31.00) | (12.80) | (6.60) | (4.67) |
| Weighted Avg Shares | 1.37M | 2.11M | 4.11M | 6.48M | 7.55M |
| Weighted Avg Shares (Diluted) | 1.37M | 2.11M | 4.11M | 6.48M | 7.55M |
Biodesix, Inc.
NASDAQ:BDSX
Intrinsic Alpha fair value
Locked
Current Price
$8.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.